RECOMBINANT RSV ANTIGENS
Search Report
EP4670734A3
Kind: A3
Mar 18, 2026
Applicants
GlaxoSmithKline Biologicals S.A.
Inventors
BAUDOUX, Jean-Pierre, BLAIS, Normand, RHEAULT, Patrick, RUELLE, Jean-Louis
Abstract
This disclosure provides recombinant respiratory syncytial virus (RSV) antigens and methods for making and using them, including immunogenic compositions (e.g. vaccines) for the treatment and/or prevention of RSV infection.
IPC Classifications
C07K 19/00 20060101AFI20260210BHEP
A61K 39/00 20060101ALI20260210BHEP
A61K 39/155 20060101ALI20260210BHEP
A61K 39/295 20060101ALI20260210BHEP
A61K 9/107 20060101ALI20260210BHEP
A61K 9/127 20250101ALI20260210BHEP
A61P 31/14 20060101ALI20260210BHEP
A61P 37/04 20060101ALI20260210BHEP
C07K 14/135 20060101ALI20260210BHEP
C12N 15/45 20060101ALI20260210BHEP
C12N 15/62 20060101ALI20260210BHEP
C07K 14/005 20060101ALI20260210BHEP
A61K 39/12 20060101ALI20260210BHEP
Designated States
AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR